The class of chemicals identified as VAMP-3 inhibitors comprises a diverse range of compounds primarily known for their ability to modulate key cellular processes such as vesicular transport, cytoskeletal dynamics, and membrane fusion. These inhibitors do not directly target VAMP-3 but influence the cellular environment and signaling networks that regulate VAMP-3's activity or expression. The primary mechanism of action for these inhibitors involves the alteration of cellular structures and pathways crucial for vesicular transport and fusion, where VAMP-3 plays a role. Compounds like Brefeldin A, Nocodazole, Monensin, and Cytochalasin D target different aspects of cellular transport machinery, such as the Golgi apparatus, microtubules, and actin filaments. By modulating these structures, these inhibitors can indirectly impact VAMP-3's function in vesicle trafficking and membrane fusion. Disruption of microtubule and actin dynamics, for instance, can lead to impaired vesicle movement and positioning, affecting VAMP-3-mediated processes.
Another aspect of VAMP-3 inhibition by these compounds is their impact on protein processing and cellular signaling. Agents like Tunicamycin, which inhibits N-linked glycosylation, and Wortmannin, a PI3K inhibitor, can indirectly inhibit VAMP-3 by altering protein trafficking and cellular signaling pathways. Additionally, compounds like Okadaic Acid, which affects protein phosphorylation, can influence phosphorylation-dependent processes involved in vesicular transport and membrane fusion. The effectiveness of these compounds in specifically inhibiting VAMP-3 depends on various factors, including the specific cellular context, concentration, and duration of exposure. It's important to consider the broader cellular effects of these compounds, as they influence a wide range of cellular processes and pathways. While these compounds offer insights into the regulation of VAMP-3 activity, their role in specifically targeting VAMP-3-mediated processes warrants further experimental validation in relevant biological models.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, affecting vesicular transport. It might indirectly inhibit VAMP-3 by altering the vesicle trafficking process, a key aspect of VAMP-3's function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules, impacting cellular transport mechanisms. Its effect on microtubule dynamics can indirectly inhibit VAMP-3 activity by affecting vesicle transport and positioning. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin, an ionophore that disrupts lysosomal function, can indirectly inhibit VAMP-3 by affecting intracellular trafficking and vesicle fusion processes, where VAMP-3 is involved. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D inhibits actin polymerization, impacting cell shape and transport. Its effect on the cytoskeleton can indirectly inhibit VAMP-3 by disrupting vesicle movement and fusion. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a protein involved in vesicle scission. By inhibiting dynamin, Dynasore might indirectly inhibit VAMP-3 by disrupting the vesicle formation and trafficking process. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A disrupts actin filaments, affecting cytoskeletal dynamics. Its influence on actin can indirectly inhibit VAMP-3 by altering vesicle movement and membrane fusion events. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, affecting protein folding and trafficking. This can indirectly inhibit VAMP-3 by disrupting the proper processing and transport of membrane proteins. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, disrupting microtubules. Its effect on microtubule dynamics can indirectly inhibit VAMP-3 by affecting vesicular transport pathways. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine, a microtubule inhibitor, can indirectly inhibit VAMP-3 by disrupting microtubule-dependent vesicle transport, impacting VAMP-3's role in vesicle fusion. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Chlorpromazine, an antipsychotic drug, can disrupt clathrin-mediated endocytosis. This disruption might indirectly inhibit VAMP-3 by affecting the vesicle formation and recycling process. | ||||||